Summary & Overview
HCPCS Level II J9175: Injection of Elliotts' B Solution, 1 ml
HCPCS Level II code J9175 designates the injection of Elliotts' B solution, billed per 1 ml. As a procedure code for injectable medication administration, it is relevant to clinicians, billing teams, and payers managing outpatient parenteral therapies. Nationwide, accurate use of this HCPCS Level II code supports proper adjudication of medication administration claims and helps ensure consistent reporting across settings.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise outline of clinical context and service setting for J9175, followed by payer-specific coverage considerations, common billing modifiers, and benchmarking references where available. The publication highlights reimbursement patterns, coding nuances for injectable therapies, and policy updates that influence claim processing for HCPCS Level II drug administration codes.
This summary framework is intended to inform billing staff, practice managers, and policy analysts about the clinical and administrative implications of using J9175, what to expect from major national payers, and which operational areas commonly require attention when billing for 1 ml injections of Elliotts' B solution.
Billing Code Overview
HCPCS Level II code J9175 denotes an injection of Elliotts' B solution, billed per 1 ml. This code represents a medication administration service in which the specified solution is prepared and delivered via injection. The service type is injectable medication administration, and the typical site of service is an outpatient clinic or physician office where parenteral treatments are administered. Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult receiving a single-dose intramuscular or subcutaneous injection of a specialty biologic formulation labeled as "elliotts' b solution" for treatment of a chronic inflammatory or autoimmune condition managed in an outpatient infusion or injection clinic. The encounter begins with verification of the medication order, patient identity, and allergy status, followed by medication preparation by a licensed clinician or pharmacy staff. The medication is drawn into a syringe and administered using standard aseptic technique. Observation for immediate adverse reaction follows for 15–30 minutes. Documentation includes the drug name and HCPCS code J9175, lot number, expiration date, route, site of administration, dose in milliliters, and any applicable modifier(s). Typical sites of service include physician office, outpatient clinic, and ambulatory infusion center. Common clinical indications include initiation or maintenance therapy for autoimmune disease, symptom control in chronic inflammatory conditions, or replacement therapy when a specific biologic is indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unspecified | Rarely used; only when no other modifier applies and payer allows |